Palisade Bio's Ulcerative Colitis Drug PALI-2108 Gains Traction with Key Conference Presentations
Event summary
- Palisade Bio's two abstracts on PALI-2108 selected for poster presentations at Crohn’s & Colitis Congress® 2026 (Jan 23) and ECCO Congress 2026 (Feb 20).
- Presentations highlight gut-targeted PDE4B inhibition and Phase 1a findings in ulcerative colitis.
- PALI-2108 designed for localized delivery to terminal ileum and colon, aiming to minimize systemic side effects.
- Company reports 100% clinical response in recent Phase 1b trial for ulcerative colitis with no serious adverse events.
The big picture
Palisade Bio's abstract selections underscore growing interest in gut-targeted PDE4 inhibitors for inflammatory bowel disease. The company's focus on localized delivery aims to address tolerability issues that have limited systemic PDE4 inhibitors. Success in Phase 2 trials could position PALI-2108 as a differentiated therapy in a market with limited non-immunosuppressive options for ulcerative colitis and Crohn's disease.
What we're watching
- Clinical Validation
- Whether PALI-2108's Phase 2 trial can replicate the 100% clinical response rate observed in Phase 1b.
- Regulatory Pathway
- The pace at which Palisade Bio advances PALI-2108 through clinical trials and potential regulatory submissions.
- Market Differentiation
- How PALI-2108's gut-targeted approach positions it against existing and emerging therapies for ulcerative colitis.